Jing Deng

2PUBLICATIONS
38CO-AUTHORS
Haematological tumoursBiomolecular modelling and design
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (2)

|Oct 14, 2022
Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies.

Yifan Zhai, Qiuqiong Tang, Douglas D Fang

|Sep 01, 2022
Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy.

Jing Deng, Aneel Paulus, Douglas D Fang

Pageof 1